Paper Details

  1. Home
  2. Paper Details

Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia.

Author: BoguradzkiP, BłońskiJ Z, CalbeckaM, CeglarekB, DmoszyńskaA, Dwilewicz-TrojaczekJ, Góra-TyborI, KasznickiM, KonopkaL, KuliczkowskiK, Moskwa-SrokaB, NowakW, RobakT, SkotnickiA B, Stella-HołowieckaB, SułekJ, WołowiecD

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the effectiveness and toxicity of a combined chemotherapy regimen (CMC) consisting of cladribine, mitoxantrone, and cyclophosphamide in treating previously untreated B-cell chronic lymphocytic leukemia (B-CLL). The study found that CMC achieved an overall response rate of 64.5%, with 29% of patients achieving complete remission. While the regimen was effective, it also resulted in significant toxicity, particularly with the CMC5 protocol. The authors recommend further investigation of the CMC3 regimen for treating B-CLL patients.
Paper Details　
Original Abstract of the Article :
The objective of the study was to determine the effectiveness and the toxicity of a combined chemotherapy consisting of cladribine (2-CdA), mitoxantrone and cyclophosphamide (CMC regimen) in the treatment of previously untreated B cell chronic lymphocytic leukemia (B-CLL). From August 1998 to Decemb...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1038/sj.leu.2402216

データ提供：米国国立医学図書館（NLM）

Exploring the Efficacy and Toxicity of a Combined Chemotherapy Regimen for Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) can be a challenging disease to treat, often requiring a combination of therapies. This research delves into the effectiveness and toxicity of a combined chemotherapy regimen consisting of cladribine (2-CdA), mitoxantrone, and cyclophosphamide (CMC) in patients with previously untreated B cell CLL. The researchers evaluated the response rates and side effects of this regimen, comparing the outcomes of patients receiving different doses of cladribine. This study provides valuable insights into the efficacy and safety of this combined chemotherapy regimen for CLL, offering guidance for clinicians in making informed treatment decisions.

A Novel Approach to CLL Treatment: Exploring the CMC Regimen

This research explores the potential of the CMC regimen as a treatment option for CLL, offering a new approach to managing this complex disease. The study's findings suggest that the CMC regimen, like a skilled caravan navigating a treacherous desert, can effectively combat CLL, achieving significant response rates. However, the study also highlights the importance of careful monitoring for potential side effects, particularly with higher doses of cladribine.

Navigating the Desert of CLL Treatment: Balancing Efficacy and Safety

This research underscores the importance of striking a balance between efficacy and safety in CLL treatment. It's like navigating a desert, where a well-planned journey can lead to success, but unexpected challenges can arise. The study's findings suggest that the CMC regimen can be an effective treatment option, but careful monitoring for potential side effects is crucial. This study encourages clinicians to weigh the benefits and risks of this regimen, tailoring treatment plans to individual patient needs.

Dr.Camel's Conclusion

This research offers a glimpse into the evolving landscape of CLL treatment, exploring the potential of novel combinations of therapies. The study's findings highlight the importance of balancing efficacy and safety in treatment decisions, ultimately seeking a path that maximizes the benefits for patients while minimizing the risks. As we continue to navigate the vast desert of medical knowledge, studies like this guide us towards a more refined understanding of the potential benefits and risks of various treatments, ultimately improving patient care.

Date :
  1. Date Completed 2002-02-22
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

11587207

DOI: Digital Object Identifier

10.1038/sj.leu.2402216

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.